Hyperprolactinemia Medication

  • Author: Donald Shenenberger, MD, FAAD, FAAFP; Chief Editor: George T Griffing, MD   more...
 
Updated: Aug 15, 2011
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Next

Dopamine agonists

Class Summary

These agents directly stimulate postsynaptic dopamine receptors. Dopaminergic neurons in tuberoinfundibular processes modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor, believed to be dopamine.[9, 10]

View full drug information

Bromocriptine (Parlodel)

 

Semisynthetic ergot alkaloid derivative; strong dopamine D2-receptor agonist; partial dopamine D1-receptor agonist. Inhibits prolactin secretion with no effect on other pituitary hormones. May be given with food to minimize possibility of GI irritation.

View full drug information

Cabergoline (Dostinex)

 

Semisynthetic ergot alkaloid derivative; strong dopamine D2-receptor agonist with low affinity for D1 receptors.

Quinagolide (Norprolac)

 

Pituitary selective dopamine-2 receptor agonist used in cases of bromocriptine resistance or intolerance. Used in the UK, not available in US.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Donald Shenenberger, MD, FAAD, FAAFP  Staff Dermatologist, Department of Dermatology, Naval Medical Center Portsmouth

Donald Shenenberger, MD, FAAD, FAAFP is a member of the following medical societies: American Academy of Dermatology, American Academy of Family Physicians, Association of Military Dermatologists, and Uniformed Services Academy of Family Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

David M Klachko, MD, MEd  Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Missouri-Columbia School of Medicine

David M Klachko, MD, MEd is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Federation for Medical Research, Endocrine Society, Missouri State Medical Association, and Sigma Xi

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Yoram Shenker, MD  Chief of Endocrinology Section, Veterans Affairs Medical Center of Madison; Interim Chief, Associate Professor, Department of Internal Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Wisconsin at Madison

Yoram Shenker, MD is a member of the following medical societies: American Heart Association, Central Society for Clinical Research, and Endocrine Society

Disclosure: Nothing to disclose.

Mark Cooper, MBBS, PhD, FRACP  Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Acknowledgments

The editors would like to thank Treyce Knee, MD, for previous contributions to this article.

References

  1. Nilsson LA, Roepstorff C, Kiens B, et al. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm Metab Res. Jun 23 2009;[Medline].

  2. [Guideline] Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. Feb 2011;96(2):273-88. [Medline].

  3. Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). Dec 18 2009;[Medline].

  4. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol. Aug 2011;165(2):209-15. [Medline].

  5. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab. August 2007;92(8):2861-5. [Medline].

  6. Sathyapalan T, Gonzalez S, Atkin SL. Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric. Jul 21 2009;1-4. [Medline].

  7. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). Apr 17 2009;[Medline].

  8. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. Jul 2009;94(7):2428-36. [Medline].

  9. Lafeber M, Stades A, Valk G, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. Jan 13 2010;[Medline].

  10. Valassi E, Klibanski A, Biller BM. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. Mar 2010;95(3):1025-33. [Medline].

  11. Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. Jan 2010;95(1):43-51. [Medline].

  12. Biller MKB, Daniels GH. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. In: Braunwald E, Isselbacher KJ, Wilson J, et al. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998:1974-8.

  13. Blackwell RE. Hyperprolactinemia. Evaluation and management. Endocrinol Metab Clin North Am. Mar 1992;21(1):105-24. [Medline].

  14. Bolanowski M, Zadrozna-Sliwka B, Jawiarczyk A, et al. The influence of other than prolactin hormones on bone mineral density in women with hyperprolactinaemia of various origins. Gynecol Endocrinol. Mar 10 2010;[Medline].

  15. Conner P, Fried G. Hyperprolactinemia; etiology, diagnosis and treatment alternatives. Acta Obstet Gynecol Scand. Mar 1998;77(3):249-62. [Medline].

  16. Davies PH. Drug-related hyperprolactinaemia. Adverse Drug React Toxicol Rev. Jun 1997;16(2):83-94. [Medline].

  17. Hartog M, Hull MG. Hyperprolactinaemia. BMJ. Sep 17 1988;297(6650):701-2. [Medline].

  18. Jones TH. The management of hyperprolactinaemia. Br J Hosp Med. Apr 19-May 2 1995;53(8):374-8. [Medline].

  19. Kaye TB. Hyperprolactinemia. Causes, consequences, and treatment options. Postgrad Med. May 1996;99(5):265-8. [Medline].

  20. Lancet. Management of prolactinoma. Lancet. Sep 15 1990;336(8716):661. [Medline].

  21. Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am. Mar 1999;28(1):143-69, vii. [Medline].

  22. Prescrire International. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine. Prescrire Int. 2000;Feb;9(45):195-7. [Medline].

  23. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. Sep 16 2003;169(6):575-81. [Medline].

  24. Valdemarsson S. Macroprolactinemia. Risk of misdiagnosis and mismanagement in hyperprolactinemia. Lakartidningen. 2004;101(6):458-65. [Medline].

  25. Wilson JD. Endocrine Disorders of the Breast. In: Braunwald E, Isselbacher KJ, Wilson J, et al,. Harrison's Principles of Internal Medicine. 1998. 14th ed. New York, NY: McGraw-Hill; 2116-7.

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.